Nabriva Therapeutics plc Nabriva Therapeutics plc

Nabriva Therapeutics plc

NBRV

Pozycja w akcjach #39896
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
Cena akcji
$0.63
Ostatnia synchronizacja: 2023-08-29
Kapitalizacja rynkowa
$284.20K
Zmiana (1 dzień)
-21.25%
Zmiana (1 rok)
629,900.02%
Kraj
IE
Handel Nabriva Therapeutics plc (NBRV)

Kategoria

Healthcare
Historia ceny akcji dla Nabriva Therapeutics plc (NBRV)
Najwyższa cena zamknięcia: $0.00 dnia 2026-10-01

Najniższa cena zamknięcia: $0.74 dnia 2023-08-01
Historia cen akcji firmy Nabriva Therapeutics plc od 2023 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) 0.00%
2025 60.55%
2024 9.75%
2023 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$527.18 23.62%
US
$251.29 835.90%
US
$137.83 -3.78%
AU
$890.85 9.42%
NL
$756.75 7.56%
CH